STOCK TITAN

INOVIO to Present at Upcoming Scientific Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

INOVIO (NASDAQ:INO), a biotechnology company developing DNA medicines, announced its participation in four upcoming scientific conferences. These include:

1. AACR Special Conference in Boston, MA (Oct 19, 2024): Dr. Matthew Morrow will present a poster on INO-3107's impact on reducing surgical interventions for Recurrent Respiratory Papillomatosis (RRP).

2. ISV Congress 2024 in Seoul, Korea (Oct 22, 2024): Dr. Michael Sumner will give an oral presentation and poster on the clinical assessment of INO-3107 in adult RRP patients.

3. Fall Voice in Phoenix, AZ (Oct 25-26, 2024): Dr. Jeffrey Skolnik will present a poster on the clinical assessment of INO-3107 in adult RRP patients.

4. World Vaccine Congress Europe in Barcelona, Spain (Oct 28, 2024): Dr. Dave Liebowitz will give a presentation and participate in a panel discussion on platform technologies.

Abstracts from these conferences will be available on INOVIO's website after each presentation.

INOVIO (NASDAQ:INO), una azienda biotecnologica che sviluppa medicinali a base di DNA, ha annunciato la sua partecipazione a quattro prossime conferenze scientifiche. Queste includono:

1. Conferenza Speciale AACR a Boston, MA (19 ottobre 2024): Il Dr. Matthew Morrow presenterà un poster sull'impatto di INO-3107 nella riduzione degli interventi chirurgici per la Papillomatosi Respiratoria Ricorrente (RRP).

2. Congresso ISV 2024 a Seoul, Corea (22 ottobre 2024): Il Dr. Michael Sumner terrà una presentazione orale e presenterà un poster sulla valutazione clinica di INO-3107 nei pazienti adulti con RRP.

3. Fall Voice a Phoenix, AZ (25-26 ottobre 2024): Il Dr. Jeffrey Skolnik presenterà un poster sulla valutazione clinica di INO-3107 nei pazienti adulti con RRP.

4. World Vaccine Congress Europe a Barcellona, Spagna (28 ottobre 2024): Il Dr. Dave Liebowitz terrà una presentazione e parteciperà a una discussione di panel sulle tecnologie di piattaforma.

Gli abstract di queste conferenze saranno disponibili sul sito web di INOVIO dopo ogni presentazione.

INOVIO (NASDAQ:INO), una empresa biotecnológica que desarrolla medicamentos a base de ADN, anunció su participación en cuatro próximas conferencias científicas. Estas incluyen:

1. Conferencia Especial AACR en Boston, MA (19 de octubre de 2024): El Dr. Matthew Morrow presentará un póster sobre el impacto de INO-3107 en la reducción de intervenciones quirúrgicas por Papilomatosis Respiratoria Recurrente (RRP).

2. Congreso ISV 2024 en Seúl, Corea (22 de octubre de 2024): El Dr. Michael Sumner dará una presentación oral y presentará un póster sobre la evaluación clínica de INO-3107 en pacientes adultos con RRP.

3. Fall Voice en Phoenix, AZ (25-26 de octubre de 2024): El Dr. Jeffrey Skolnik presentará un póster sobre la evaluación clínica de INO-3107 en pacientes adultos con RRP.

4. Congreso Mundial de Vacunas Europa en Barcelona, España (28 de octubre de 2024): El Dr. Dave Liebowitz dará una presentación y participará en una discusión de panel sobre tecnologías de plataforma.

Los resúmenes de estas conferencias estarán disponibles en el sitio web de INOVIO después de cada presentación.

INOVIO (NASDAQ:INO), DNA 의약품을 개발하는 생명공학 회사가 향후 진행될 네 개의 과학 회의에 참여할 것이라고 발표했습니다. 다음과 같은 일정이 포함됩니다:

1. AACR 특별 회의 미국 매사추세츠주 보스턴 (2024년 10월 19일): 매튜 모로우 박사가 INO-3107이 재발성 호흡기 유두종증(RRP)의 외과적 개입을 줄이는 데 미치는 영향에 대한 포스터를 발표합니다.

2. ISV Congress 2024 한국 서울 (2024년 10월 22일): 마이클 섬너 박사가 성인 RRP 환자에서 INO-3107의 임상 평가에 대한 구술 발표 및 포스터를 제공합니다.

3. Fall Voice 미국 애리조나주 피닉스 (2024년 10월 25-26일): 제프리 스콜닉 박사가 성인 RRP 환자에서 INO-3107의 임상 평가에 대한 포스터를 발표합니다.

4. World Vaccine Congress Europe 스페인 바르셀로나 (2024년 10월 28일): 데이브 리보위츠 박사가 발표를 하고 플랫폼 기술에 관한 패널 토론에 참여합니다.

이 회의의 초록은 각 발표 후 INOVIO의 웹사이트에서 확인할 수 있습니다.

INOVIO (NASDAQ:INO), une entreprise biotechnologique développant des médicaments à base d'ADN, a annoncé sa participation à quatre prochaines conférences scientifiques. Celles-ci incluent :

1. Conférence Spéciale AACR à Boston, MA (19 octobre 2024) : Dr. Matthew Morrow présentera une affiche sur l'impact de INO-3107 dans la réduction des interventions chirurgicales pour la Papillomatose Respiratoire Récurrente (RRP).

2. Congrès ISV 2024 à Séoul, Corée (22 octobre 2024) : Dr. Michael Sumner fera une présentation orale et présentera une affiche sur l’évaluation clinique de INO-3107 chez les patients adultes atteints de RRP.

3. Fall Voice à Phoenix, AZ (25-26 octobre 2024) : Dr. Jeffrey Skolnik présentera une affiche sur l’évaluation clinique de INO-3107 chez les patients adultes atteints de RRP.

4. Congrès Mondial des Vaccins Europe à Barcelone, Espagne (28 octobre 2024) : Dr. Dave Liebowitz fera une présentation et participera à un débat sur les technologies de plateforme.

Les résumés de ces conférences seront disponibles sur le site Web d'INOVIO après chaque présentation.

INOVIO (NASDAQ:INO), ein biotechnologisches Unternehmen, das DNA-Medikamente entwickelt, gab seine Teilnahme an vier bevorstehenden wissenschaftlichen Konferenzen bekannt. Diese umfassen:

1. AACR Spezialkonferenz in Boston, MA (19. Oktober 2024): Dr. Matthew Morrow wird ein Poster über die Auswirkungen von INO-3107 auf die Reduzierung chirurgischer Eingriffe bei rekurrierender respiratorischer Papillomatose (RRP) präsentieren.

2. ISV Kongress 2024 in Seoul, Korea (22. Oktober 2024): Dr. Michael Sumner wird eine mündliche Präsentation und ein Poster zur klinischen Bewertung von INO-3107 bei erwachsenen RRP-Patienten halten.

3. Fall Voice in Phoenix, AZ (25.-26. Oktober 2024): Dr. Jeffrey Skolnik wird ein Poster zur klinischen Bewertung von INO-3107 bei erwachsenen RRP-Patienten präsentieren.

4. World Vaccine Congress Europe in Barcelona, Spanien (28. Oktober 2024): Dr. Dave Liebowitz wird eine Präsentation halten und an einer Podiumsdiskussion über Plattformtechnologien teilnehmen.

Abstracts von diesen Konferenzen werden nach jeder Präsentation auf der Website von INOVIO verfügbar sein.

Positive
  • None.
Negative
  • None.

PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences:

AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy
Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO
Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways
Date and Time: October 19, 2024, 6:00 - 8:15pm ET
Location: Boston, MA

ISV Congress 2024
Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 22, 2024, 4:20pm KST
Location: Seoul, Korea

Fall Voice
Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 25 – October 26, 2024
Location: Phoenix, AZ

World Vaccine Congress Europe
Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIO
Track: Pre-Congress Workshop on Platform Technologies
Date and Time: October 28, 2024, 10:00am CET
Location: Barcelona, Spain

Abstracts from these conferences will be made available on INOVIO's website following each presentation.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302263723.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What conferences will INOVIO (INO) present at in October 2024?

INOVIO will present at four conferences in October 2024: AACR Special Conference in Boston, ISV Congress in Seoul, Fall Voice in Phoenix, and World Vaccine Congress Europe in Barcelona.

What is the focus of INOVIO's (INO) presentations at these conferences?

INOVIO's presentations primarily focus on INO-3107, their DNA medicine for treating Recurrent Respiratory Papillomatosis (RRP), including its clinical assessment and impact on reducing surgical interventions.

Who will be presenting on behalf of INOVIO (INO) at these conferences?

Presenters include Dr. Matthew Morrow, Dr. Michael Sumner, Dr. Jeffrey Skolnik, and Dr. Dave Liebowitz, all holding senior positions at INOVIO.

When and where will INOVIO (INO) present at the ISV Congress 2024?

INOVIO will present at the ISV Congress 2024 on October 22, 2024, at 4:20pm KST in Seoul, Korea.

What is the topic of INOVIO's (INO) presentation at the World Vaccine Congress Europe?

At the World Vaccine Congress Europe, INOVIO will participate in a pre-congress workshop on platform technologies, with Dr. Dave Liebowitz giving a presentation and joining a panel discussion.

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

INO Rankings

INO Latest News

INO Stock Data

111.45M
25.88M
0.85%
33.51%
13.5%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States of America
SAN DIEGO